Home
Resource
Design and synthesis of novel pan-targeting anti-influenza agents
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(4.64 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Sagong, Hye Yeon. Design and synthesis of novel pan-targeting anti-influenza agents. Retrieved from https://doi.org/doi:10.7282/T3GF0WZ7

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleDesign and synthesis of novel pan-targeting anti-influenza agents
NameSagong, Hye Yeon (author); LaVoie, Edmond J. (chair); Rice, Joseph E. (internal member); Hu, Longqin (internal member); Arnold, Edward (internal member); Pilch, Daniel S. (outside member); Rutgers University; Graduate School - New Brunswick
Date Created2017
Other Date2017-01 (degree)
SubjectMedicinal Chemistry, Endonucleases, Influenza--Treatment
Extent1 online resource (xiv, 275 p. : ill.)
DescriptionPandemics and seasonal epidemics of influenza pose a major health concern worldwide. The limitation of vaccination and the emergence of influenza virus strains that are resistant to the current antivirals, have emphasized the search for a new antiviral with novel mechanisms of action. The endonuclease activity of polymerase acidic protein (PA) has been identified as an attractive target. PAN endonuclease is a highly conserved and essential viral transcription protein, which cleaves host pre-mRNA during the cap-snatching process. The cap-snatching mechanism is a unique process of the viral transcription. There are many known PAN endonuclease inhibitors, and few of them inhibited viral reproduction in the cell. iii Our research efforts began with conducting a fragment screening campaign using 2009 pandemic H1N1 PAN. The compound 5-chloro-3-hydroxypyridin-2(1H)-one was identified as a bimetal chelating ligand at the active site of the enzyme. Several scaffolds were proposed from the hit compound including 3-hydroxypyridin-2(1H)-ones, 3-hydroxyquinolin-2(1H)-ones and aza analogous of 3-hydroxypyridin-2(1H)-ones. Although initial SAR studies on 3-hydroxypyridin-2(1H)-ones led to compound 13 with a modest antiviral activity in the cellular assay (EC50 = 11 μM), neither 3-hydroxyquinolin-2(1H)-ones nor aza analogous of 3-hydroxypyridin-2(1H)-ones displayed any ex-vivo activity. Our research again focused on the initial scaffold, 3-hydroxypyridin-2(1H)-ones. Optimization of binding interaction at the 5- and 6-positions of the pyridinone ring provided compounds having inhibitory activity that is comparative compound 13 in the enzymatic assay. Unfortunately, these compounds were not active in the cellular assay. Our research then turned to preparing noncompetitive inhibitors to validate whether irreversible or a more sustained modification of PAN could result in ex-vivo activity. In the meantime, 3-hydroxypyridin-2(1H)-one derivatives with an additional chelating moiety, which could have enhanced binding interactions with PAN, were prepared. This concept, however, turned out to be unsuccessful as we could not see any ex-vivo activity with these compounds as well. Although our various attempts at designing PAN endonuclease inhibitor with a great ex-vivo activity were unsuccessful, continued efforts are being made to find a PAN endonuclease inhibitor, which could be developed into the clinic.
NotePh.D.
NoteIncludes bibliographical references
Noteby Hye Yeon Sagong
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3GF0WZ7
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024